GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (CHIX:GMABc) » Definitions » Price-to-Free-Cash-Flow

Genmab AS (CHIX:GMABC) Price-to-Free-Cash-Flow : 12.01 (As of Jun. 01, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genmab AS Price-to-Free-Cash-Flow?

As of today (2025-06-01), Genmab AS's share price is kr1402.00. Genmab AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr116.78. Hence, Genmab AS's Price-to-Free-Cash-Flow Ratio for today is 12.01.

The historical rank and industry rank for Genmab AS's Price-to-Free-Cash-Flow or its related term are showing as below:

CHIX:GMABc' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.49   Med: 62.52   Max: 10322.03
Current: 11.81

During the past 13 years, Genmab AS's highest Price-to-Free-Cash-Flow Ratio was 10322.03. The lowest was 10.49. And the median was 62.52.

CHIX:GMABc's Price-to-Free-Cash-Flow is ranked better than
76.82% of 233 companies
in the Biotechnology industry
Industry Median: 30.6 vs CHIX:GMABc: 11.81

Genmab AS's Free Cash Flow per Share for the three months ended in Mar. 2025 was kr27.73. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr116.78.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Genmab AS was 39.90% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 56.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 55.20% per year.

During the past 13 years, Genmab AS's highest 3-Year average Free Cash Flow per Share Growth Rate was 191.80% per year. The lowest was -80.80% per year. And the median was 37.40% per year.


Genmab AS Price-to-Free-Cash-Flow Historical Data

The historical data trend for Genmab AS's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Price-to-Free-Cash-Flow Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.21 87.74 53.43 19.99 13.00

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.96 17.24 15.16 13.00 11.47

Competitive Comparison of Genmab AS's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Genmab AS's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Genmab AS's Price-to-Free-Cash-Flow falls into.


;
;

Genmab AS Price-to-Free-Cash-Flow Calculation

Genmab AS's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1402.00/116.778
=12.01

Genmab AS's Share Price of today is kr1402.00.
Genmab AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr116.78.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Genmab AS  (CHIX:GMABc) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Genmab AS Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Genmab AS's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines